Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents

Diabetes exacts a huge toll on medical care resources, together with exceptionally significant costs owing to maintenance of diabetes in percentage to the affected populace. Though human therapy plans are necessary for every single affected person, newer longacting sulfonylureas might be the first drugs of preference, since they might be the only oral agents which inhibit the procedures causing hyperglycemia–hepatic glucose production and glucose utilization by the cells –simply by boosting insulin secretion and insulin resistance.

Sulfonylureas additionally represent the cheapest curative option, independently or in conjunction with other oral agents or insulin. The newer longacting representatives, glimepiride and glipizide GITS, may possibly be attractive among sulfonylureas, because of their greater insulin-sparing land, fewer hypoglycemic events, weight neutrality, and once-daily dosing. Glimepiride may be preferred as a result of its safety profile, particularly for the older and people who have post-traumatic or renal dysfunction.


Our most popular topics on Managedcaremag.com